




# IARC Medium-Term Strategy (MTS) for 2021–2025

Dr Elisabethe Weiderpass, Director  
International Agency for Research on Cancer  
Lyon, France

# Medium-Term Strategy 2021–2025

## Preparatory work



# Medium-Term Strategy 2021–2025

## Preparatory work: External Evaluation



**Recommendations  
informed MTS discussions**



Inclusive, transparent and focused strategic prioritization process



Strengthened collaboration with WHO (Science Division)



Future-focused balance between in-house and external laboratory capacities



Additional laboratory, bioinformatics, and other expertise through collaboration, Visiting Scientists, and secondments from Participating States

# Medium-Term Strategy 2021–2025

## Preparatory work: Stakeholders' consultation – Conclusions



Conclusions informed MTS discussions



On strategic priorities

- Continue focus on **IARC's fundamental priorities**
- Strengthen engagement in **emerging priorities**, emphasize **implementation research**



On positioning IARC:

- Communicate **IARC's mandate and role** more effectively
- Highlight IARC's **public health impact**
- Enhance **IARC's visibility in non-scientific** cancer community



On strategic partnerships:

- Explore **strategic engagement** with non-traditional partners
- Seek **Cooperation Agreements and specific collaboration projects**

# Medium-Term Strategy 2021–2025

## Preparatory work: A new Mission for IARC


### Cancer Research that Matters



- Research that ultimately makes a difference in people's lives. Research that positively affects life expectancy
- *How?*  
Intentionally pursue cancer research and science that is expected to positively and notably affect people's health
- Strengthen engagement, resources and collaboration in priority areas when conducting scientific and research work


# Medium-Term Strategy 2021–2025

## Preparatory work : IARC's Comparative Advantages



# Medium-Term Strategy 2021–2025

## Results: Fundamental Priorities



# Medium-Term Strategy 2021–2025

## Results: Emerging priorities





# Medium-Term Strategy 2021–2025

## Joint GC/SC Working Group on the MTS



- Strategic guidance and advice on IARC's new MTS 2021–2025
- Four remote Working Group meetings and three reviews of the draft MTS
  - Including two comprehensive reviews through all relevant WHO Divisions and Departments
- Draft MTS 2021–2025 represents the result of productive discussions, exchanges of views and a forward-looking collaboration between IARC's governing bodies and the Secretariat

# Medium-Term Strategy 2021–2025

## Finalization



# Implementing the Medium-Term Strategy 2021–2025

## A gradual approach

- **Prioritization of IARC activities: a gradual approach**
- IARC will continue **strategic fundamental activities** in:
  - Describing the cancer burden
  - Understanding the causes of cancer
  - Evaluating cancer prevention interventions
  - Synthesizing and mobilizing knowledge and strengthening global capacities for cancer
- IARC will gradually **strengthen IARC's engagement** in the **three emerging priorities identified**, with a stronger emphasis on **implementation research**
  - Evolving cancer risk factors and populations in transition
  - Implementation research
  - Economic and societal impacts of cancer

# Implementing the Medium-Term Strategy 2021–2025 will facilitate the transition towards a stronger IARC

- Global hub for open science for cancer prevention
- Leader in prevention research
- Recognized for public health impact
- Global capacity builder for cancer science and research

